We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 23, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
SILENT FC VARIANTS OF ANTI-CD40 ANTIBODIES
MARKERS ASSOCIATED WITH CYCLIN-DEPENDENT KINASE INHIBITORS
ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
ANTIBODY DRUG CONJUGATES
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
IMMUNE-STIMULATING MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2
ANTI-CDH6 ANTIBODY DRUG CONJUGATES
INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES
TREATMENT OF BREAST CANCER BRAIN METASTASES
RNA-GUIDED GENE EDITING SYSTEM AND USES THEREOF